Top Markets
Coin of the day
Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

600276
Rang in Aktien #509
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
Aktienkurs
$7.88
Zuletzt synchronisiert: 2026-08-12
Marktkapitalisierung
$50.25B
Veränderung (1 Tag)
-1.11%
Veränderung (1 Jahr)
-9.73%
Land
CN
Handel Jiangsu Hengrui Medicine Co., Ltd. (600276)

Kategorie

Dividendenrendite-Verlauf für Jiangsu Hengrui Medicine Co., Ltd. (600276)
Dividendenrendite (TTM) von Jiangsu Hengrui Medicine Co., Ltd. (Aktienkürzel: 600276) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Jiangsu Hengrui Medicine Co., Ltd. (600276) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber